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Purpose: Among HIV-infected persons, antiretroviral therapy (ART) and depression are strongly
associated with mortality. We estimated reductions in 5-year mortality in Women’s Interagency HIV
Study participants under plausible hypothetical increases in ART initiation and reductions in depression
(CES-D score16).
Methods: We followed 885 ART-naïve Women’s Interagency HIV Study participants for 5 years from their
first study visit after April 1998 to death or censoring. We used the parametric extended g-formula to
estimate cumulative mortality under the natural course (NC) and alternative exposure distributions.
Results: Baseline prevalence of depression was 52% and 62% initiated ART by 5 years. Compared with
mortality under NC (13.2%), immediate ART and elimination of 36% or 67% of depressive episodes were
associated with risk differences (RDs) of 5.2% (95% CI: 7.7%, 2.6%) and 5.7 (95% CI: 8.7, 2.7).
Compared with immediate ART and NC for depression, additionally eliminating 67% of the depressive
episodes was associated with RD ¼ 1.6 (95% CI: 3.9, 0.8). Compared with 5-year mortality under
NC for ART and elimination of 67% of depression, also initiating ART immediately was associated with
RD ¼ -2.6 (95% CI: -5.0, -0.3).
Conclusions: Increasing ART initiation and reducing depression were associated with moderate
reductions in 5-year mortality among HIV-infected women.Introduction is associated with lower probabilities of ART initiation and ARTAntiretroviral therapy (ART) has reduced immunodeficiency-
associated morbidity and mortality in persons infected with HIV
[1, 2], exposing the importance of managing comorbid conditions.
Depression is two to four times more common in HIV-infected
persons than in the general population [3]. Untreated depressiononsibility of the authors and
titutes of Health (NIH).
icle were reported.
y, Johns Hopkins Bloomberg
D 21205.adherence [4,5]. Furthermore, depression is associated with faster
progression of HIV disease [6] and AIDS-related and non-
AIDSerelated mortality [7], even after adjusting for ART use and
adherence. ART and depression may interact biologically or
psychosocially [3]. It is necessary to consider ART and depression
changes together to explore this interaction [8,9].
A recent analysis by Todd et al. [8] in the Women’s Interagency
HIV Study (WIHS) was one of the first to explicitly consider joint
effects [10] of ART and depressive symptoms. In that study, the
relative hazard (HR) of mortality associated with depressive
symptoms was similar to the HR associated with no ART. Todd et al.
[8] contrasted mortality hazards under four extreme counterfactual
exposure distributions: 1) everyone initiates ART immediately and
never has depressive symptoms; 2) everyone initiates ART
immediately and always has depressive symptoms; 3) everyone
delays ART initiation indefinitely (i.e., never initiates ART) and
never has depressive symptoms; and 4) everyone delays ART
initiation indefinitely and always has depressive symptoms.
Our goal in the present analysis was to extend this prior work by
estimating 5-year, all-cause mortality under several less extreme,
hypothetical interventions to jointly increase ART uptake and reduce
depressive symptoms, compared with the natural course (i.e., the
5-year mortality under the observed exposure distributions) [11].
This type of contrast has been called a “generalized intervention
contrast” [12].
Hypothetical interventions
We estimated effects of two sets of hypothetical interventions on
5-year mortality. First, we imposed no direct intervention on ART
initiation (ART initiation was allowed to be affected indirectly
through interventions on depression) and simultaneously either: 1)
eliminated depressive symptomswith probability 36% at a given visit
when a woman would have reported being depressed if all in-
terventions on depression were discontinued right before that visit
(the natural value of depression) [13]; 2) eliminated depressive
symptomswith probability 67% at a given visit when awomanwould
have reported her natural value of depression as depressed; or 3)
eliminated 100% of depressive symptoms for all women at all visits.
Next, we set ART initiation to be immediate for all women and
simultaneous reduced either 0% (no direct intervention on depres-
sion), 36%, 67% or 100% of depressive symptoms at a given visit for
woman visits when the natural value of depressionwould have been
depressed if all interventions on depression were discontinued right
before that visit. All interventions assumed no loss to follow-up.
Reductions of 36% and 67% in depressive symptoms generally
correspond to the reductions in depression seen among outpatients
with nonpsychotic major depressive disorder in the Sequenced
Treatment Alternatives to Relieve Depression (STAR*D) trial (see
Discussion). Thirty-six percent of participants experienced
depressive symptom elimination following first-line depression
treatment and 67% experienced symptom elimination after




A full description of the WIHS cohort, recruitment, study enroll-
ment, and study procedures is provided elsewhere [15,16]. Briefly,
between 1994 and 2015, theWIHS enrolled 4982 women in ten sites
across the United States, of who approximately three in four were
HIV-seropositive at enrollment. Women attended semiannual
follow-up visits, at which time-detailed measurements on HIV dis-
ease history and progression, medications, laboratory results, and
behavioral characteristics,were collected. Institutional review boards
at each site approved the WIHS, and this analysis was approved by
the institutional review board of the University of North Carolina.
We took 1 April 1998 to be the start of the modern ART era and
eligibility for this analysis. HIV-seropositive, ART-naïve WIHS par-
ticipants with detectable viral load at their earliest WIHS visit on or
after 1 April 1998 (defined as baseline for this analysis) were
included. Thus study sample was a mix of women enrolled in the
first wave of WIHS who remained ART-naïve through April 1998
and womenwho were ART-naïve when they enrolled in the second
(2001/2002) or third (2011/2012) wave of WIHS recruitment. Of3567 seropositive WIHS participants, 928 were ART-naïve at their
first visit during the analytic period. We excluded 43 (5%) who did
not have at least one depression measure, one CD4 cell count, and
one HIV RNA viral load determinationwithin 1 year of baseline. The
final study population included 885 participants.
Mortality ascertainment
Mortality for women enrolled in the WIHS is obtained from
clinic sources, follow-up with family members for participants lost
to follow up, and regular matches against the National Death Index.
Statistical analysis
We followed women from their first eligible WIHS visit on or
after 1 April 1998 until first of death, loss to follow up (defined as
12 months since the most recent WIHS visit), or administrative
censoring at five years follow-up or site-specific administrative end
of follow-up (most recent check for deaths in the National Death
Index; 31 December 2010 for 12% of women and 31 December 2012
for 88%). Time-fixed baseline covariates included: race (black
or other); age in years; current smoking; and at-risk drinking
(>7 drinks/week) [17]. Time-varying covariates included CD4 cell
count (cells/mL), HIV viral load (log10 copies/mL), and illicit drug use
(any use of crack, cocaine, heroin, amphetamines, or other drugs,
excluding marijuana, since the last visit). Women reported whether
they had initiated ART since their last visit, where ART was defined
as 3 antiretroviral medications, one of which was a protease
inhibitor, a nonnucleoside reverse transcriptase inhibitor, abacavir,
tenofovir, an integrase inhibitor (e.g., raltegravir) or an entry
inhibitor (e.g., Maraviroc or enfuvirtide) [18]. Presence of depres-
sive symptoms was defined as a score of 16 on the Center for
Epidemiological Studies Depression scale (CES-D), measured at
each visit [19]. The CES-D has been shown to have reasonably high
sensitivity (95%) and specificity (70%) among low-income women
[20]; positive predictive value of the CES-D should be high in the
WIHS where prevalence of depression is high.
We used the parametric g-formula and the parametric extended
g-formula to estimate 5-year cumulative mortality under several
scenarios [21,22]. In instances where confounders also serve as
mediators, in contrast to standard methods, g-methods remain
unbiased [23,24]; for the current research question, CD4 cell count
and viral load are confounders and mediators of the effect of ART,
and illicit drug use may be a confounder and mediator of the effect
of depressive symptoms. We employed the parametric extended
g-formula [11,23] because it allows the estimation of the effects of
hypothetical exposure distributions thatmay depend on the natural
value of exposure. The trade-off for increased flexibility of the
parametric g-formula is increased assumptions about correct joint-
model fit. As an informal check on the plausibility of the modeling
assumptions required in the parametric g-formula, we compared
results from the g-formula with results from a marginal structural
model, for always/never exposure distributions for ART and
depression (static deterministic regimes). Because the parametric
g-formula and marginal structural models rely on different
modeling assumptions, agreement between the two results
increases confidence in model specification [25]. The marginal
structural model we fit for comparison modeled joint effects on
5-year mortality of always versus never having depressive
symptoms and immediately versus never initiating ART. The
denominator of the weights for ART were estimated using logistic
models for the probability of ART initiation conditional on time
since baseline, black race, age, illicit drug use reported at baseline,
baseline smoking, baseline heavy drinking, baseline CD4 cell count,
baseline viral load, and 6-month’ lagged depressive symptoms, CD4
cell count, and detectable viral load. The denominator for the
weights for depressionwere estimated using logistic models for the
probability of depressive symptoms, stratified by 6-month’ lagged
history of depressive symptoms, conditional on time since baseline,
black race, age, illicit drug use reported at baseline, baseline
smoking, baseline heavy drinking, baseline CD4 cell count, baseline
viral load, ART initiation, and 6-month’ lagged CD4 cell count, and
detectable viral load. Both sets of weights were stabilized by time
since baseline; inverse probability of depression weights was also
stabilized by ART initiation. Censoring weights were conditional on
the same set of confounders as both treatment weights, as well as
prior ART initiation, prior depression, and a product term for the
two exposures. All continuous variables were modeled with
restricted cubic splines with knots at the fifth, 35th, 65th and 95th
percentile of their distribution [26]. The final weights were the
product of the ART, depression, and censoring weights.
A formal description of methods for the parametric extended
g-formula appears in the appendix. Descriptions of the parametric
g-formula and parametric extended g-formula have been published
elsewhere [11,21,22,27e29]. Briefly, we first fit parametric (pooled
logistic or linear) models in the following order for: 1) reporting
recent illicit drug use at visit j ¼ 1.J conditional all time-fixed
covariates and time-varying covariates at visit j 1 (see Table 1)
including an interaction term between depression and ART (note:
this and subsequent models were also implicitly conditional on
survival and retention in the cohort until visit j); 2) undetectable
HIV RNA viral load (<200 copies/mL) at visit j, conditional on time-
fixed covariates, time-varying covariates other than illicit drug use
at visit j 1, and illicit drug use at visit j; 3) CD4 cell count at visit j,
conditional on time-fixed covariates, time-varying covariates other
than illicit drug use and viral load at visit j 1, and illicit drug use
and detectable viral load at visit j; 4) depressive symptoms at visit j
(exposure), conditional on time-fixed covariates, ART initiation
before.j, and time-varying covariates at visit j; 5) ART initiation in
the interval from j to jþ 1 (exposure), conditional on time-fixed
covariates, time-varying covariates at visit j, and not yet having
initiated ART; 6) remaining uncensored until visit jþ 1, conditional
on time-fixed covariates, time-varying covariates at visit j, and
ART initiation in the interval starting with j; and 7) death before
visit jþ 1 (outcome), conditional on time-fixed covariates, time-
varying covariates at visit j, and ART initiation in the interval
starting with j. We saved parameter estimates from each model forTable 1
Characteristics of 885 Women’s Interagency HIV Study (WIHS) participants who
were ART-naïve at baseline and followed for up to 5 years
Characteristic WIHS participants
at baseline n ¼ 885
Person-years of
follow-up* n ¼ 3377
Black racey 571 (65) 2193 (64)
Age, yearsz 38 (32, 45) 40 (34, 46)
Baseline past or current smokingy 658 (74) 2591 (75)
Baseline heavy drinking
(>7 drinks/week)y
121 (14) 420 (12)
Illicit drug use in past 6 monthsy,x 199 (22) 614 (18)
Most recent CD4 cell countz 441 (273, 649) 433 (277, 623)
Most recent log10 viral loadz 3.5 (2.7, 4.3) 3.3 (2.3, 4.2)
Current depressive symptomsy,k 457 (52) 1639 (48)
CES-D scorez 16 (7, 27) 15 (6, 25)
ART ¼ antiretroviral treatment; CES-D ¼ Center for Epidemiological Studies
Depression scale; HIV ¼ human immunodeficiency virus.
* For time-updated covariates, N (%) and median (IQR) are summaries of the
covariate across all person-years of follow-up.
y N (%).
z Median (IQR).
x Participant reporteduseof crack, cocaine, heroin,methadone,methamphetamine,
or other drug use (excluding marijuana) since the previous visit.
k Defined as CES-D16.use in the Monte Carlo simulation. We explored alternative order-
ings of modeling time-varying covariates [27] and saw little change
in final estimates.
We used Monte Carlo simulation to estimate cumulative mor-
tality curves approximated by the joint distribution of the models
above.We sampledWIHS participants at baselinewith replacement
50,000 times, discarding follow-up data. We simulated follow-up
data for each of the 50,000 resamples based on the parameters
estimated from the models above to estimate the natural course.
Inability to recapture the observed distributions of time-varying
covariates or cumulative incidence of the outcome implies model
misspecification. Thus, we compared observed and natural course
cumulative incidence curves for ART initiation, drop-out and mor-
tality, and mean variable values over time for CD4 cell count, viral
suppression, illicit drug use, and depression. We did a further check
of model specification by setting covariate values for ART initiation
and depression (in addition to removing all drop-out) to estimate
cumulative incidence of mortality under exposure distributions
corresponding to immediately/never initiating ART and always/
never having depressive symptoms for comparison with marginal
structural model effect estimates [8]. Finally, we estimated cumu-
lative mortality curves under interventions by first predicting the
natural value of depression at visit j (i.e., the value of depression
that would have been observed if the intervention were dis-
continued right before j) and then modifying the probability of
depression at visit jþ 1 if the woman was depressed at visit j [13].
We estimated the standard error of estimates from the standard
deviation from 200 bootstrap resamples [30]. Unrestricted random
samples were drawn with replacement from the study sample.
Models described above were fit and Monte Carlo simulation was
run within each bootstrap resample. All analyses were carried out
using SAS 9.3 (SAS Institute Inc., Cary, NC).Results
Of 885 women in the WIHS who met inclusion criteria and had
complete data, 65% were black, 74% reported ever smoking, 14%
reported at-risk drinking, and 22% reported recent illicit drug use.
Median agewas 38 years (interquartile range [IQR]: 32, 45). Median
CD4 cell count and viral load were 441 cells/mL (IQR: 273, 649) and
3.5 log10 copies/mL (IQR: 2.7, 4.3), respectively. Over half of
participants had prevalent depressive symptoms at the first visit
(52%). Median CES-D score was 16 (IQR: 7, 27; Table 1).
During 3377 person-years of follow-up, 191 patients were lost to
follow up, and 92 patients died. Overall, 5-year mortality risk was
12.6% (95% CI: 10.1%, 15.1%). Cumulative incidence of ART initiation
by 5 years was 62% (Fig. 1). Prevalence of depressive symptoms was
steady across the study period, around 45% (Fig. 1). We were able to
recapture the observed data with the parametric g-formula for all
modeled covariates, exposures, and outcome.
Using the parametric g-formula, we estimated that, compared
with never initiating ART and always being depressed, never initi-
ating ART and never being depressed was associated with a 5-year
mortality risk difference of 12.3 (95% CI: 19.7, 4.9), immediately
initiating ART and always being depressed was associated with a 5-
year mortality risk difference of 10.8 (95% CI: 18.7, 2.9), and
immediately initiating ART and never being depressed was associ-
ated with a 5-year mortality risk difference of 16.0 (95%
CI: 23.2, 8.9; Table 2).
When we estimated the same exposure contrasts using a joint
marginal structural model, all estimates were slightly larger
(Table 2). Cumulative mortality curves for each of the four always/
never exposure effects from the parametric g-formula andmarginal
structural models coincide at 5 years, but there are some
Fig. 1. Natural history (observed) and natural course (modeled/predicted) for (A) ART initiation and (B) prevalence of depression.differences in predicted mortality associated with the treatment
policy that never initiate ART/or never be depressed (Fig. 2).
Generalized intervention contrasts were attenuated compared
with exposure effects (Table 3). If depressive symptoms were
treatedwith 36%, 67%, or 100% probability of elimination at the next
visit (Fig. 3) and if ART initiation was immediate, associated 5-year
mortality risk differences were4.2 (95% CI: 6.3,2.0),5.2 (95%
CI: 7.7, 2.6), and 6.0 (95% CI: 9.4, 2.6), respectively.
Compared with only intervening to reduce depression by 67% at the
next visit, also intervening to initiate everyone on ART immediately
was associated with risk difference of 2.6 (95% CI: 5.0, 0.3).
Compared with only intervening to initiate everyone on ART, also
reducing depressive symptoms by 67% at the next visit would
further reduce 5-year mortality by 1.6 (95% CI: 3.9, 0.8). For
completeness, we present cumulative incidence functions for
modeled interventions in Figure 4 and risk differences, risk ratios,
and hazard ratios in Table 3.
Discussion
We used Robins’ parametric g-formula [21,22] to substantiate
the strong association between constant exposure to depressiveTable 2
Exposure effects of art and depression on 5-year risk of mortality estimated among 885
Exposure distribution 5-year mortality risk
Parametric g-formula
No ART, always depressive symptoms 23.2 (16.9, 29.4)
No ART, never depressive symptoms 10.9 (6.5, 15.2)
Immediate ART, always depressive symptoms 12.4 (6.7, 18.0)
Immediate ART, never depressive symptoms 7.1 (3.8, 10.5)
No ART 18.6 (14.0, 23.1)
Immediate ART 9.0 (6.3, 11.8)
Always depressive symptoms 16.4 (12.5, 20.3)
Never depressive symptoms 9.4 (6.3, 12.6)
Inverse probability weighted marginal structural model
No ART, always depressive symptoms 25.0 (9.6, 40.4)
No ART, never depressive symptoms 12.1 (5.1, 19.2)
Immediate ART, always depressive symptoms 11.1 (5.8, 16.3)
Immediate ART, never depressive symptoms 4.7 (2.0, 7.5)
No ART 17.5 (11.7, 23.3)
Immediate ART 8.2 (5.4, 11.1)
Always depressive symptoms 17.7 (12.7, 22.6)
Never depressive symptoms 8.4 (5.1, 11.7)
ART ¼ antiretroviral treatment.symptoms and long-term delay of ART initiation and higher
mortality estimated with a marginal structural model [8]. How-
ever, contrasts of mortality under various reductions in depression
symptoms and increases in ART compared with mortality under
the natural course provide more realistic, generalizable [12]
estimates of the effect that interventions might produce. Mortal-
ity reductions attainable with immediate ART initiation in
contemporary HIV-infected cohorts may be even less because ART
use is more common (and fewer people have not yet started ART
under the natural course). Mortality reductions associated with
depression treatment, assuming ART initiation was immediate for
all women, were modest; in particular, there was arguably not a
meaningful difference between a reduction in episodes of
depression of 37% or 67%. This may be due to subadditive causal
interactions between the two exposures or it may be due to the
relatively minor differences in depression prevalence under the
two hypothetical interventions (Fig. 3). However, our results
indicated that improving ART coverage and reducing depressive
symptoms were both associated with clinically meaningful
mortality reductions that were similar in magnitude, and reducing
depressive symptoms reduced mortality (marginally) even in the
presence of 100% ART coverage.ART-naïve women enrolled in the Women’s Interagency HIV Study (WIHS)
Risk difference Risk ratio Hazard ratio
0 1 1
12.3 (19.7, 4.9) 0.47 (0.37, 0.59) 0.50 (0.28, 0.89)
10.8 (18.7, 2.9) 0.53 (0.40, 0.71) 0.44 (0.24, 0.75)
16.0 (23.2, 8.9) 0.31 (0.26, 0.37) 0.28 (0.15, 0.52)
0 1 1
9.6 (14.9, 4.3) 0.49 (0.33, 0.72) 0.46 (0.30, 0.71)
0 1 1
7.0 (12.0, 2.0) 0.57 (0.38, 0.87) 0.55 (0.35, 0.86)
0 1 1
12.8 (29.8, 4.2) 0.49 (0.21, 1.13) 0.45 (0.19, 1.05)
13.9 (29.8, 2.0) 0.44 (0.21, 0.92) 0.39 (0.17, 0.89)
20.2 (36.0, 4.4) 0.19 (0.08, 0.45) 0.17 (0.07, 0.42)
0 1 1
9.3 (15.6, 2.9) 0.47 (0.29, 0.76) 0.45 (027, 0.74)
0 1 1
9.3 (15.5, 3.0) 0.48 (0.28, 0.80) 0.46 (0.27, 0.78)
Fig. 2. Cumulative mortality curves from (A) the parametric g-formula and (B) inverse probability weighted marginal structural model under intervention regimens: 1) immediately
initiate ART and never be depressed; 2) immediately initiate ART and always be depressed; 3) never initiate ART and never be depressed; and 4) always initiate ART and always be
depressed.ART use has an undisputed direct effect (not through
depression) on mortality [2,31], and it is possible that it also has
a weak indirect effect on mortality by reducing depressive
symptoms [32]. In addition the indirect effects of depression on
mortality through HIV progression and treatment, depression
may have a direct effect (not through HIV) on mortality.
Depression in HIV-infected adults has also been linked
with higher non-AIDSerelated mortality, including mortality
due to liver disease, drug overdose, violence (homicide/suicide/
accident), and non-AIDSerelated malignancy [7]. Because of
these interactions between depression and ART use, a major
strength of our analysis was our consideration of them jointly.
A set of assumptions sufficient for a causal interpretation of our
results includes conditional exchangeability [13,24], treatment
version irrelevance [33], positivity [22,34], correct model specifi-
cation [24], no measurement error [35], and no interference [36].
We frame the limitations of this analysis in terms of potential
violations of these assumptions. Perhaps most significant is that
depression treatment was not collected during part of the study
period, and the format in which it was collected was inconsistent
across time; thus we focused our analysis on depressive symptoms
rather than depression treatment. This decision could result inTable 3
Generalized effect of several plausible interventions on antiretroviral treatment and dep
enrolled in the Women’s Interagency HIV Study (WIHS)
Exposure distribution Parametr
5-year m
Natural course 13.2 (10.6
Natural course for ART and.
Reduce depression 36% at next visit 11.4 (8.9,
Reduce depression 67% at next visit 10.1 (7.2,
Eliminate all depression 9.4 (6.3,
Immediate ART and.
Natural course for depression 9.0 (6.3,
Reduce depression 36% at next visit 8.0 (5.3,
Reduce depression 67% at next visit 7.4 (4.4,
Eliminate all depression 7.1 (3.7,
Immediate ART and reduce depression 67% at next visit versus.
Natural course for ART and reduce depression 67% at next visit (ref)
Immediate ART and natural course for depression (ref)
ART ¼ antiretroviral treatment; CES-D ¼ Center for Epidemiological Studies Depressionviolations of several assumptions. First, women who were never
depressed may be meaningfully different from formerly depressed
women whose depressive symptoms are eliminated, violating the
exchangeability assumption. However, HIV-infected women
receiving treatment for depression (specifically serotonin reuptake
inhibitors) had ART adherence and laboratory value trajectories
similar to nondepressed women [5]. Furthermore, while we are
fairly confident that key confounders of the effect of ART on
mortality are measured, it is less plausible that we accounted for all
possible confounders of the effect of depression on mortality;
time-varying smoking, risky sexual behaviors, and engagement in
medical care are just some possible confounders whose influence
should be explored in future analyses. Second, because we did not
model a specific intervention on depression, assuming treatment
version irrelevance is more problematic. Acknowledging this
limitation, we chose to model reductions in depression that
coincided with effects seen in the STAR*D trial [14]. If women with
depressive symptoms were already receiving depression treatment
and were resistant to treatment, first-line depression treatment
may be less effective for an unidentifiable subgroup of the cohort.
However, less than 20% of HIV-infected women with prevalent
depression are estimated to be receiving any depressive treatmentression (CES-D score16) on 5-year risk of mortality among 885 ART-naïve women
ic g-formula
ortality risk Risk difference Risk ratio Hazard ratio
, 15.9) 0 1 1
14.0) 1.8 (3.4, 0.2) 0.87 (0.76, 0.99) 0.86 (0.74, 0.99)
12.9) 3.1 (5.4, 0.9) 0.76 (0.62, 0.94) 0.75 (0.60, 0.94)
12.6) 3.7 (6.5, 1.0) 0.72 (0.54, 0.95) 0.70 (0.52, 0.94)
11.8) 4.2 (6.3, 2.0) 0.68 (0.55, 0.86) 0.67 (0.53, 0.85)
10.7) 5.2 (7.7, 2.6) 0.61 (0.45, 0.81) 0.59 (0.44, 0.80)
10.5) 5.7 (8.7, 2.7) 0.57 (0.39, 0.82) 0.55 (0.37, 0.81)
10.5) 6.0 (9.4, 2.6) 0.54 (0.34, 0.86) 0.53 (0.33, 0.85)
2.6 (5.0, 0.3) 0.74 (0.54, 1.01) 0.73 (0.53, 1.01)
1.6 (3.9, 0.8) 0.83 (0.60, 1.1) 0.82 (0.59, 1.14)
scale; HIV ¼ human immunodeficiency virus.
Fig. 3. Prevalence of depressive symptoms (CES-D score 16) under the natural course
and various interventions to reduce the probability of depressive symptoms at the next
visit given depressive symptoms at a given visit. Shaded areas indicate pointwise 95%
confidence intervals.[37], and thus depressive symptoms are likely indicative of
untreated depression. Our modeled intervention did not exactly
correspond to the STAR*D trial result in that the probability of
remission found per individual in the STAR*D trial was applied to
each depressive episode in our analysis, and thus the overall
individual probability of remission of depressive symptoms over a
5-year period in our cohort was higher than was found in the trial
(Fig. 3). As a consequence, our results may be overly optimistic
about the reduction in mortality attainable by treating depression
in this population. Alternatively, we could have assigned eachFig. 4. Cumulativemortality curves from the parametric g-formula for the natural course
(no intervention) and interventions thatwould treat everyonewith ART immediately and
treat depressive symptoms with success rates of 34%, 67%, and 100%.woman a latent probability of having depression that was respon-
sive to treatment, but such an approach has not been implemented
nor formalized before. Third, because we modeled the effect of a
change in depressive symptoms rather thanmodeling the effect of a
specific intervention on clinical depression, if CES-D were a poor
indicator of the presence of clinical depression, we may have mis-
classified women as eligible for intervention when they were not.
However, to the first point, the CES-D has been shown to have high
sensitivity (95%) and specificity (70%) for clinical depression among
low-income women [20]. Finally, we believe that in this analysis,
there is little potential for violations of the assumptions of positivity
and no interference.
One strength of our analysis was our decision to fit both a
marginal structural model and the parametric g-formula for
comparisons of always/never having depressive symptoms and no/
immediate ART initiation (static deterministic treatment regimes).
We did not check our findings from the parametric extended
g-formula (in which the intervention depends on the natural value
of exposure) against a comparable marginal structural model [22],
which would be computationally more complicated. Fitting either a
marginal structural model or using g-computation should arguably
be standard operating procedure when employing the parametric
g-formula to triangulate toward the truth [22,25,27]. The para-
metric g-formula assumes correct model specification for the
outcome and all time-varying covariates; in contrast, marginal
structural models rely on correct specification of the model(s) for
exposure and (possibly) censoring. If results from alternate esti-
mators disagree, this is an indication that at least one assumption of
at least one of the estimators is violated. Using double robust
methods or an alternate study design [for example, instrumental
variable methods [38,39] or structural nested models [40]] may
give clues as to which estimator is biased.
We chose to estimate joint effects of ART and depression given
their high potential to interact in determining mortality. We report
a generalized impact contrast, which is arguably more useful to
policy makers than exposure effects. While intervention effects
associated with realistic interventions on ART and depressive
symptoms were attenuated compared with exposure effects, they
were still clinically significant. Our results provide further evidence
supporting immediate ART initiation for persons with HIV, and
some evidence that depression screening and treatment may
provide marginal additional benefit for the prevention of all-cause
mortality.
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AppendixWe follow the convention of denoting random variables with uppercase letters and possible realizations of those random variables
with lowercase letters. Let i ¼ 1;.; N index WIHS participants, and let j ¼ 1;.; J denote completed months of follow-up. For
participant i, let Yij be an indicator of death in month j; let Cij be an indicator of censoring (having gone 12 months since the last study
visit) in month j; let Aij be an indicator of antiretroviral therapy (ART) in month j; let Dij be an indicator of depression in month j; and
finally, let Zij be a vector of time-fixed and time-varying covariates that confound the effect of A on Y or that confound the effect of D on
Y , in month j. By design, Aið1Þ ¼ Yi0 ¼ Ci0 ¼ 0, since we restricted to persons who were ART naïve and alive and at risk for death at
baseline. By definition, if Yik ¼ 1 then Yiðkþ1Þ ¼ 1, and if Cik ¼ 1 then Ciðkþ1Þ ¼ 1. Also, because we analyzed the data using an intent-
to-treat approach for initiation of ART, if Aik ¼ 1 then Aiðkþ1Þ ¼ 1 by definition.






































>>>>>;where Pð,j,Þ is the conditional probability evaluated at the observed covariates values for a given participant; f ð,j,Þ is the conditional
density function; and FðjÞ is the cumulative incidence function of death evaluated at time j. We assumed that censoring was not informative
of subsequent outcome, exposure or covariates, given measured covariate and exposure history.
Many typical epidemiologic analyses estimate exposure effects. That is, they ask the question, “what would be the difference in the
incidence of death in the study sample had everyone initiated ART immediately and no one been depressed ever, versus had no one
initiated ART and everyone always been depressed?” To answer that question, we would estimate the cumulative incidence of death






























>>>>;We use g to indicate interventions on a and d, g ¼ ðga; gdÞ. Note that herewe comparemortality under exposure regimens agj ¼ ð1;.;1Þ
and d
g
j ¼ ð0;.;0Þ (always treated and never depressed) versus agj ¼ ð0;.;0Þ and d
g
j ¼ ð1;.;1Þ (never treated and always depressed), for
example. Ensuring no loss to follow-up, that is, intervening to set cj ¼ ð0;.;0Þ, is a component of both regimens.
In this paper, we aimed to estimate an intervention effect (21). That is, we asked the question, “what would be the difference in the
incidence of death in the study sample had we intervened to get all women initiated on ART immediately, treated depression with effec-
tiveness T% for all womenwith depressive symptoms, and had no one been lost to follow-up, versus the incidence of death in the absence of









































The intervention depends on the natural value of depression at time k, which is defined as the value of depression that would have been
observed if the intervention were discontinued right before k (13). We denote the natural value of depression at time k as D*k. a
g
m is set
according to exposure regimens a1;gdj ¼ ð1;.;1Þ and a
0;gd
j ¼ ð0;.;0Þ, and d
g
m is set according to exposure regimens:




1; if dgm ¼ 0
0; if dgm ¼ 1




ð1 Tg=100Þ; if dgm ¼ 1
Tg=100; if dgm ¼ 0Pg

Dgm ¼ dgm
D*m ¼ d*m;Zm ¼ zm;Dgm1 ¼ dgm1;Agm1 ¼ agm1;




D*m ¼ d*m;Zm ¼ zm;Dgm1 ¼ dgm1;Agm1 ¼ agm1;
gBy definition d1 ¼ d1 ¼ 0. The intervention specified above is equivalent to: “Initiate everyone on ART immediately, and among those
who are depressed (assuming any intervention on depressionwere discontinued right before depressionwas measured), treat them all with
T% probability of remitting depressive symptoms.” Individuals who are treated for depression are not prevented from relapsing and
experiencing depressive symptoms at a future visit.
